Abstract: Provided herein are methods and compositions related to Prevotella histicola extracellular vesicles (EVs), and solutions and dried forms (and therapeutic compositions thereof) of Prevotella histicola extracellular vesicles (EVs) for the reduction of IL-8, IL-6, IL-1?, and/or TNF? expression and/or for the treatment of viral infections.

Abstract: An orthotic support insole having a body including each of an uppermost anti-microbial lining, an intermediate foam layer, a rigid stabilizer insert and a bottom-most thermo-formable foam layer. An extending edge of the body corresponds to at least a heel cup and intermediate sides being fused along an outer perimeter edge to prevent delamination. The body includes a non-standard thickness along an axial length thereof and the fused perimeter edge extends to a location proximate a forward extending edge portion of the body.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Abstract: A multi-function cane for the visually impaired can have an adjustable elongate shaft, a distal tip with a free end for contacting the walking surface, and a compression brake disposed between the shaft and the distal tip. The distal tip can have a distal portion rotatable about the axis of the cane shaft. The compression brake can allow the distal tip of the multi-function cane to rotate so the cane operates as a mobility cane when the brake is disengaged. The application of a compressive longitudinal force can engage the brake to prevent rotation of the distal tip so the cane can be load-bearing to operate as a support cane.

Abstract: Provided herein are methods and compositions related to Prevotella bacteria for the reduction of IL-8, IL-6, IL-I?, and/C or TNF? expression and/or for the treatment of viral infections.

Abstract: An orthotic support insole having a body including each of an uppermost anti-microbial lining, an intermediate foam layer, a rigid stabilizer insert and a bottom-most thermo-formable foam layer. An extending edge of the body corresponds to at least a heel cup and intermediate sides being fused along an outer perimeter edge to prevent delamination. The body includes a non-standard thickness along an axial length thereof and the fused perimeter edge extends to a location proximate a forward extending edge portion of the body.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Abstract: Controlled release dosage formulations for the delivery of active agents, especially for treatment of eye diseases or disorders, such as glaucoma, have been developed. These provide release of the active agent, such as ECA or a derivative thereof, for an effective period of time.

Abstract: Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.

Abstract: Methods are provided for identifying aptamer regulators. Aptamer regulators are aptamers that bind to a target wherein binding of the aptamer regulator to the target increases the binding affinity of the target for a target partner relative to the affinity of the target for the target partner when the target is not bound by the aptamer regulator such that binding of the aptamer regulator to the target is a prerequisite for target-target partner complex formation.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.